Pharma

Your Article Summary

See Latest Articles

Inspire Committed to Helping Healthcare Providers and Patients During Erythromycin Ophthalmic Ointment Shortage
Inspire, 09/10/09

Inspire Pharmaceuticals announced that it has been communicating with the U.S. Food and Drug Administration and is increasing its production of AzaSite 1% in response to the manufacturing supply shortage of erythromycin ophthalmic ointment. Erythromycin ophthalmic ointment is a macrolide antibiotic routinely used in neonates for prophylaxis of ophthalmia neonatorum, a form of bacterial conjunctivitis that may be contracted by newborns during delivery.

Today in Drug/Product Approvals...keeping you current

Receive free subspecialty "5-minute updates" via email

Cell Therapeutics Announces FDAs Oncologic Drugs Advisory Committee to Review Pixantrone for the Treatment of Relapsed/Refractory Aggressive Non-Hodgkins Lymphoma, February 2010
Cell Therapeutics, 12/18/09

Eslicarbazepine: A novel antiepileptic agent designed for improved efficacy and safety
Formulary , 12/16/09

Human genome sciences announces submission of marketing authorization application to emea for joulferon
Human Genome Sciences, 12/16/09

 See all of Drug/Product Approvals